That means current switching protocols come from trial designs and the expected behavior based on retatrutides pharmacology: 6-day half-life, triple receptor activity (GLP-1 plus GIP plus glucagon), and stepwise titration from 2 mg to 12 mg
More recently, the SELECT trial confirmed cardiovascular benefits of Wegovy in patients with overweight/obesity and established cardiovascular disease without diabetes, leading to its 2024 FDA indication for cardiovascular risk reduction in this population
They want a clinic that offers real support, real treatment options, and a practical path they can actually follow
Effective Weight Reduction Clinical studies have shown that semaglutide can lead to significant weight loss, with patients experiencing an average reduction of 15-20% of their body weight over several months
January 22, 2026
In the 1980s, Breakthrough T1D-funded researcher Pauline Kay Lund, Ph.D., was the first to clone the hormone glucagon and discover two new hormones, one of which was GLP-1
:max_bytes(150000):strip_icc()/WhatstheDifferenceBetweenOzempicWegovyandMounjaro-illo-a8f5a23fe4914586b4488472fe15f112.png)
